Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · as published 2026-01-23 View official record Methodology

Covered recipient · General Payments record

VANITA R ARODA

Allopathic & Osteopathic Physicians Internal Medicine Endocrinology, Diabetes & Metabolism

NPI
1588748883
CMS profile
116914
Location
BOSTON, MA

General Payments · PY2018–2024

$499,817.86

  • Reported across 289 records
  • CMS publication 2026-01-23

Latest program year · PY2024

$73,965.91

34 records · 0 disputed

Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.

How these totals are calculated
  • The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
  • Methodology & Data — sourcing, labeling, and limitations.

By nature of payment

PY2024 · sorted by reported total

By paying entity

PY2024 · sorted by reported total

Paying entityAmountRecords
Novo Nordisk AS $23,453.49 9
SERVIER AFFAIRES MEDICALES $18,500.00 1
Acerta Pharma LLC $12,241.45 13
PFIZER INC. $8,410.00 6
AstraZeneca AB $7,974.46 3
Corcept Therapeutics $3,386.51 2

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2018 $82,893.21 54
PY2019 $123,673.22 106
PY2020 $62,876.85 19
PY2021 $37,756.14 20
PY2022 $55,446.64 30
PY2023 $63,205.89 26
PY2024 $73,965.91 34

Payment records · PY2024 (34)

Sorted by paying entity, then date · as published by CMS

Program year 2024 201820192020202120222023 Record-level detail is published for PY2024; earlier years are summarised in “By program year”.
Paying entity Amount Date Nature of payment Dispute status Published Record ID Source
AstraZeneca AB $724.95 12/02/2024 Consulting Fee Undisputed 01/23/2026 1093882261 CMS
AstraZeneca AB $5,799.61 12/20/2024 Consulting Fee Undisputed 01/23/2026 1093932397 CMS
AstraZeneca AB $1,449.90 12/20/2024 Consulting Fee Undisputed 01/23/2026 1094002873 CMS
AstraZeneca Pharmaceuticals LP $96.03 06/25/2024 Food and Beverage Undisputed 01/23/2026 1104332786 CMS
AstraZeneca Pharmaceuticals LP $167.50 06/25/2024 Travel and Lodging Undisputed 01/23/2026 1104355198 CMS
AstraZeneca Pharmaceuticals LP $501.05 06/25/2024 Travel and Lodging Undisputed 01/23/2026 1104527526 CMS
AstraZeneca Pharmaceuticals LP $340.26 06/25/2024 Travel and Lodging Undisputed 01/23/2026 1104581556 CMS
AstraZeneca Pharmaceuticals LP $501.05 06/25/2024 Travel and Lodging Undisputed 01/23/2026 1105469593 CMS
AstraZeneca Pharmaceuticals LP $78.93 06/25/2024 Food and Beverage Undisputed 01/23/2026 1105629860 CMS
AstraZeneca Pharmaceuticals LP $104.69 06/25/2024 Food and Beverage Undisputed 01/23/2026 1105741886 CMS
AstraZeneca Pharmaceuticals LP $135.00 06/25/2024 Food and Beverage Undisputed 01/23/2026 1105772944 CMS
AstraZeneca Pharmaceuticals LP $69.91 06/25/2024 Food and Beverage Undisputed 01/23/2026 1105836565 CMS
AstraZeneca Pharmaceuticals LP $9,424.36 11/16/2024 Consulting Fee Undisputed 01/23/2026 1105465807 CMS
AstraZeneca Pharmaceuticals LP $724.95 12/06/2024 Consulting Fee Undisputed 01/23/2026 1104510650 CMS
AstraZeneca Pharmaceuticals LP $46.17 12/06/2024 Food and Beverage Undisputed 01/23/2026 1104623110 CMS
AstraZeneca Pharmaceuticals LP $51.55 12/06/2024 Travel and Lodging Undisputed 01/23/2026 1104749173 CMS
Corcept Therapeutics $124.01 06/21/2024 Food and Beverage Undisputed 01/23/2026 1117789427 CMS
Corcept Therapeutics $3,262.50 07/10/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program Undisputed 01/23/2026 1117789425 CMS
Novo Nordisk AS $2,250.00 02/29/2024 Consulting Fee Undisputed 01/23/2026 1096552749 CMS
Novo Nordisk AS $2,250.00 03/12/2024 Consulting Fee Undisputed 01/23/2026 1096552513 CMS
Novo Nordisk AS $27.07 10/03/2024 Travel and Lodging Undisputed 01/23/2026 1096551993 CMS
Novo Nordisk AS $397.28 10/03/2024 Food and Beverage Undisputed 01/23/2026 1096552119 CMS
Novo Nordisk AS $5,770.90 10/03/2024 Travel and Lodging Undisputed 01/23/2026 1096552145 CMS
Novo Nordisk AS $517.16 10/03/2024 Travel and Lodging Undisputed 01/23/2026 1096552871 CMS
Novo Nordisk AS $366.08 10/03/2024 Travel and Lodging Undisputed 01/23/2026 1096553179 CMS
Novo Nordisk AS $9,875.00 10/03/2024 Consulting Fee Undisputed 01/23/2026 1096553451 CMS
Novo Nordisk AS $2,000.00 10/31/2024 Consulting Fee Undisputed 01/23/2026 1096553391 CMS
PFIZER INC. $2,320.00 02/15/2024 Consulting Fee Undisputed 01/23/2026 1132055472 CMS
PFIZER INC. $1,160.00 02/20/2024 Consulting Fee Undisputed 01/23/2026 1132055470 CMS
PFIZER INC. $870.00 05/23/2024 Consulting Fee Undisputed 01/23/2026 1131415251 CMS
PFIZER INC. $1,160.00 08/29/2024 Honoraria Undisputed 01/23/2026 1131622118 CMS
PFIZER INC. $1,160.00 10/21/2024 Honoraria Undisputed 01/23/2026 1131622381 CMS
PFIZER INC. $1,740.00 11/25/2024 Consulting Fee Undisputed 01/23/2026 1130874475 CMS
SERVIER AFFAIRES MEDICALES $18,500.00 05/03/2024 Consulting Fee Undisputed 01/23/2026 1147264362 CMS

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-01-23
Program years on this page
2018, 2019, 2020, 2021, 2022, 2023, 2024
Source files
Dataset page · Bulk file · PY2018 , PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024
Generated from
OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.